Changes in weight, papilledema, headache, visual field, and life status in response to diet and metformin in women with idiopathic intracranial hypertension with and without concurrent polycystic ovary syndrome or hyperinsulinemia

Translational Research

Volumn 148, Issue 5, 2006, Pages 215-222

  Glueck, Charles J ^a   Golnik, Karl C ^b   Aregawi, Dawit ^a   Goldenberg, Naila ^a   Sieve, Luann ^a   Wang, Ping ^a  

^a JEWISH HOSPITAL   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; FUROSEMIDE; METFORMIN; TOPIRAMATE;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIET THERAPY; FEMALE; HEADACHE; HUMAN; HYPERINSULINEMIA; INTRACRANIAL HYPERTENSION; LIFE EVENT; LOW CALORY DIET; OVARY POLYCYSTIC DISEASE; PAPILLEDEMA; PRIORITY JOURNAL; PROTEIN DIET; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL FIELD; VISUAL FIELD DEFECT; WEIGHT CHANGE; WEIGHT REDUCTION;

EID: 33750297826     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2006.05.003     Document Type: Article

References (64)

1. Kesler A., and Gadoth N. Epidemiology of idiopathic intracranial hypertension in Israel. J Neuroophthalmol 21 (2001) 12-14
2. Goodwin J. Recent developments in idiopathic intracranial hypertension (IIH). Semin Ophthalmol 18 (2003) 181-189
3. Binder D.K., Horton J.C., Lawton M.T., and McDermott M.W. Idiopathic intracranial hypertension. Neurosurgery 54 (2004) 538-551 discussion 551-2
4. Brazis P.W., and Lee A.G. Elevated intracranial pressure and pseudotumor cerebri. Curr Opin Ophthalmol 9 (1998) 27-32
5. Bandyopadhyay S. Pseudotumor cerebri. Arch Neurol 58 (2001) 1699-1701
6. Durcan F.J., Corbett J.J., and Wall M. The incidence of pseudotumor cerebri. Population studies in Iowa and Louisiana. Arch Neurol 45 (1988) 875-877
7. Lueck C., and McIlwaine G. Interventions for idiopathic intracranial hypertension. Cochrane Database Syst Rev (2002) CD003434
8. Quattrone A., Gambardella A., Carbone A.M., Oliveri R.L., Lavano A., De Marco E.V., et al. A hypofibrinolytic state in overweight patients with cerebral venous thrombosis and isolated intracranial hypertension. J Neurol 246 (1999) 1086-1089
9. Sussman J., Leach M., Greaves M., Malia R., and Davies-Jones G.A. Potentially prothrombotic abnormalities of coagulation in benign intracranial hypertension. J Neurol Neurosurg Psychiatry 62 (1997) 229-233
10. Daif A., Awada A., al-Rajeh S., Abduljabbar M., al Tahan A.R., Obeid T., and Malibary T. Cerebral venous thrombosis in adults. A study of 40 cases from Saudi Arabia. Stroke 26 (1995) 1193-1195
11. Krajewski K.J., and Gurwood A.S. Idiopathic intracranial hypertension: pseudotumor cerebri. Optometry 73 (2002) 546-552
12. Piovesan E.J., Lange M.C., Piovesan Ldo R., de Almeida S.M., Kowacs P.A., and Werneck L.C. Long-term evolution of papilledema in idiopathic intracranial hypertension: observations concerning two cases. Arq Neuropsiquiatr 60 (2002) 453-457
13. Shin R.K., and Balcer L.J. Idiopathic intracranial hypertension. Curr Treat Options Neurol 4 (2002) 297-305
14. Friedman D.I., and Rausch E.A. Headache diagnoses in patients with treated idiopathic intracranial hypertension. Neurology 58 (2002) 1551-1553
15. Craig J.J., Mulholland D.A., and Gibson J.M. Idiopathic intracranial hypertension; incidence, presenting features and outcome in Northern Ireland (1991-1995). Ulster Med J 70 (2001) 31-35
16. Glueck C.J., Aregawi D., Goldenberg N., Golnik K.C., Sieve L., and Wang P. Idiopathic intracranial hypertension, polycystic-ovary syndrome, and thrombophilia. J Lab Clin Med 145 (2005) 72-82
17. Glueck C.J., Iyengar S., Goldenberg N., Smith L.S., and Wang P. Idiopathic intracranial hypertension: associations with coagulation disorders and polycystic-ovary syndrome. J Lab Clin Med 142 (2003) 35-45
18. Weksler B. Linking thrombophilia and idiopathic intracranial hypertension. J Lab Clin Med 145 (2005) 63-64
19. Dunkley S., and Johnston I. Thrombophilia as a common predisposing factor in pseudotumor cerebri. Blood 103 (2004) 1972-1973
20. Friedman D.I., and Jacobson D.M. Idiopathic intracranial hypertension. J Neuroophthalmol 24 (2004) 138-145
21. Friedman D.I. Pseudotumor cerebri. Neurol Clin 22 (2004) 99-131 vi
22. Friedman D.I., and Jacobson D.M. Diagnostic criteria for idiopathic intracranial hypertension. Neurology 59 (2002) 1492-1495
23. Tang R.A., Dorotheo E.U., Schiffman J.S., and Bahrani H.M. Medical and surgical management of idiopathic intracranial hypertension in pregnancy. Curr Neurol Neurosci Rep 4 (2004) 398-409
24. McGirt M.J., Woodworth G., Thomas G., Miller N., Williams M., and Rigamonti D. Cerebrospinal fluid shunt placement for pseudotumor cerebri-associated intractable headache: predictors of treatment response and an analysis of long-term outcomes. J Neurosurg 101 (2004) 627-632
25. Wall M. Idiopathic intracranial hypertension: mechanisms of visual loss and disease management. Semin Neurol 20 (2000) 89-95
26. Corbett J.J., Savino P.J., Thompson H.S., Kansu T., Schatz N.J., Orr L.S., and Hopson D. Visual loss in pseudotumor cerebri. Follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss. Arch Neurol 39 (1982) 461-474
27. Flegal K.M., Carroll M.D., Ogden C.L., and Johnson C.L. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288 (2002) 1723-1727
28. Sugerman H.J., DeMaria E.J., Felton III W.L., Nakatsuka M., and Sismanis A. Increased intra-abdominal pressure and cardiac filling pressures in obesity-associated pseudotumor cerebri. Neurology 49 (1997) 507-511
29. Karahalios D.G., Rekate H.L., Khayata M.H., and Apostolides P.J. Elevated intracranial venous pressure as a universal mechanism in pseudotumor cerebri of varying etiologies. Neurology 46 (1996) 198-202
30. Wang B., Jenkins J.R., and Trayhurn P. Expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture: integrated response to TNF-alpha. Am J Physiol Endocrinol Metab 288 (2005) E731-E740
31. Trayhurn P., and Wood I.S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92 (2004) 347-355
32. Wellen K.E., Uysal K.T., Wiesbrock S., Yang Q., Chen H., and Hotamisligil G.S. Interaction of tumor necrosis factor-alpha- and thiazolidinedione-regulated pathways in obesity. Endocrinology 145 (2004) 2214-2220
33. Wellen K.E., and Hotamisligil G.S. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 112 (2003) 1785-1788
34. Romano M., Guagnano M.T., Pacini G., Vigneri S., Falco A., Marinopiccoli M., et al. Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women. J Clin Endocrinol Metab 88 (2003) 5321-5326
35. Glueck C.J., Wang P., Fontaine R., Tracy T., and Sieve-Smith L. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism 48 (1999) 511-519
36. Glueck C.J., Wang P., Fontaine R., Tracy T., and Sieve-Smith L. Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adolesc Health 29 (2001) 160-169
37. Glueck C.J., Streicher P., and Wang P. Treatment of polycystic ovary syndrome with insulin-lowering agents. Expert Opin Pharmacother 3 (2002) 1177-1189
38. Velazquez E.M., Mendoza S.G., Wang P., and Glueck C.J. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism 46 (1997) 454-457
39. Velazquez E.M., Mendoza S., Hamer T., Sosa F., and Glueck C.J. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43 (1994) 647-654
40. Glueck C.J., Fontaine R.N., Wang P., Subbiah M.T., Weber K., Illig E., et al. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism 50 (2001) 856-861
41. Johnson L.N., Krohel G.B., Madsen R.W., and March Jr. G.A. The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri). Ophthalmology 105 (1998) 2313-2317
42. Kupersmith M.J., Gamell L., Turbin R., Peck V., Spiegel P., and Wall M. Effects of weight loss on the course of idiopathic intracranial hypertension in women. Neurology 50 (1998) 1094-1098
43. Rowe F.J., and Sarkies N.J. The relationship between obesity and idiopathic intracranial hypertension. Int J Obes Relat Metab Disord 23 (1999) 54-59
44. Glueck C.J., Goldenberg N., Golnik K., Sieve L., and Wang P. Idiopathic intracranial hypertension: associations with thrombophilia and hypofibrinolysis in men. Clin Appl Thromb Hemost 11 (2005) 441-448
45. Meyer-Heim A., Landau K., and Boltshauser E. [Treatment of acne with consequences-pseudotumor cerebri due to hypervitaminosis A]. Schweiz Rundsch Med Prax 91 (2002) 23-26
46. Somech R., Arav-Boger R., Assia A., Spirer Z., and Jurgenson U. Complications of minocycline therapy for acne vulgaris: case reports and review of the literature. Pediatr Dermatol 16 (1999) 469-472
47. Rogers A.H., Rogers G.L., Bremer D.L., and McGregor M.L. Pseudotumor cerebri in children receiving recombinant human growth hormone. Ophthalmology 106 (1999) 1186-1189 discussion 1189-90
48. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81 (2004) 19-25
49. Woodworth G.F., McGirt M.J., Elfert P., Sciubba D.M., and Rigamonti D. Frameless stereotactic ventricular shunt placement for idiopathic intracranial hypertension. Stereotact Funct Neurosurg 83 (2005) 12-16
50. Hay S.A., Hay A.A., Moharram H., and Salama M. Endoscopic implantation and patency evaluation of lumboperitoneal shunt: an innovative technique. Surg Endosc 18 (2004) 482-484
51. Higgins J.N., Cousins C., Owler B.K., Sarkies N., and Pickard J.D. Idiopathic intracranial hypertension: 12 cases treated by venous sinus stenting. J Neurol Neurosurg Psychiatry 74 (2003) 1662-1666
52. Gupta A.K., Ganth M.G., and Gupta A. Modified endoscopic optic nerve decompression in idiopathic intracranial hypertension. J Laryngol Otol 117 (2003) 501-502
53. SAS. SAS for Windows 9.1.3 (2005), SAS Institute, Cary, NC
54. Benjamini Y., and Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Series B 57 (1995) 289-300
55. Huna-Baron R., and Kupersmith M.J. Idiopathic intracranial hypertension in pregnancy. J Neurol 249 (2002) 1078-1081
56. Lee A.G., Golnik K., Kardon R., Wall M., Eggenberger E., and Yedavally S. Sleep apnea and intracranial hypertension in men. Ophthalmology 109 (2002) 482-485
57. Kesler A., Goldhammer Y., and Gadoth N. Do men with pseudomotor cerebri share the same characteristics as women?. A retrospective review of 141 cases. J Neuroophthalmol 21 (2001) 15-17
58. Johnston I., Kollar C., Dunkley S., Assaad N., and Parker G. Cranial venous outflow obstruction in the pseudotumour syndrome: incidence, nature and relevance. J Clin Neurosci 9 (2002) 273-278
59. Farb R.I., Vanek I., Scott J.N., Mikulis D.J., Willinsky R.A., Tomlinson G., and terBrugge K.G. Idiopathic intracranial hypertension: the prevalence and morphology of sinovenous stenosis. Neurology 60 (2003) 1418-1424
60. Subramaniam R.M., Tress B.M., King J.O., Eizenberg N., and Mitchell P.J. Transverse sinus septum: a new aetiology of idiopathic intracranial hypertension?. Australas Radiol 48 (2004) 114-116
61. Sylaja P.N., Ahsan Moosa N.V., Radhakrishnan K., Sankara Sarma P., and Pradeep Kumar S. Differential diagnosis of patients with intracranial sinus venous thrombosis related isolated intracranial hypertension from those with idiopathic intracranial hypertension. J Neurol Sci 215 (2003) 9-12
62. Knochenhauer E.S., Key T.J., Kahsar-Miller M., Waggoner W., Boots L.R., and Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83 (1998) 3078-3082
63. la Marca A., Morgante G., Palumbo M., Cianci A., Petraglia F., and De Leo V. Insulin-lowering treatment reduces aromatase activity in response to follicle-stimulating hormone in women with polycystic ovary syndrome. Fertil Steril 78 (2002) 1234-1239
64. Frisen L. Clinical features of optic neuritis standard examination techniques. Bull Soc Belge Ophtalmol 208 Pt 1 (1983) 131-142